Congo poised to mobilise diagnostics in face of "high-mortality unknown illness":
This article was originally published in Clinica
Executive Summary
International epidemiology experts are awaiting the results of laboratory tests on samples related to an "unknown high-mortality" disease in the Democratic Republic of Congo. Healthcare and surveillance teams from the health ministry and the Institut National de Recherches Biologiques, backed by the WHO, are investigating the situation, which is centred in Kasai Occidental province. The exact number of cases and deaths is not yet known, according to a WHO notice, dated August 31, but the majority involves infants under the age of 10, presenting with fever, headache, diarrhoea/abdominal pain and vomiting. The Global Outbreak Alert and Response Network (GOARN) and the WHO are supporting the government's epidemiological investigations and logistics efforts.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.